Phio Pharmaceuticals Corp. - Common Stock (NQ:PHIO)

0.9851 -0.0149 (-1.49%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Phio Pharmaceuticals Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Why Is Phio Pharmaceuticals Stock Soaring Today? ↗

November 03, 2025

Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an update on an ongoing medical trial.

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Discover the top movers in Monday's pre-market session. ↗

November 03, 2025

As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

November 03, 2025

Pathologic Clearance: 100% Tumor Clearance (Complete Response) in One Patient, Greater than 90% (Near Complete Response) in Second Patient, Greater...

Via Newsfile

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

October 31, 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - October 31, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

October 21, 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

September 23, 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - September 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

September 18, 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - September 18, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company...

Via Newsfile

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

Clinical trial advances to anticipated final cohort for INSTASYL siRNA lead product candidate PH-7625th cohort patients now being treated in...

Via Newsfile

Phio Posts Wider Loss in Fiscal Q2 ↗

August 14, 2025

Via The Motley Fool

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025

Clinical trial advances for INSTASYL siRNA lead product candidate PH-7625th cohort enrolling patients in on-going clinical studyKing of Prussia, Pennsylvania--(Newsfile...

Via Newsfile

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

July 25, 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company...

Via Newsfile

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 25, 2025

Via Benzinga

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

July 25, 2025

Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell...

Via Newsfile

Gapping stocks in Friday's session ↗

July 25, 2025

Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

Friday's pre-market session: top gainers and losers ↗

July 25, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 25, 2025

Via Benzinga

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

July 25, 2025

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical...

Via Newsfile

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

June 25, 2025

-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough,...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

June 24, 2025

Marlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...

Via Newsfile

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

June 05, 2025

Via Benzinga

Which stocks are gapping on Thursday? ↗

June 05, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Sidoti Events, LLC's Virtual May Micro-Cap Conference

May 20, 2025

Via ACCESS Newswire

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 19, 2025

Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...

Via Newsfile

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025

Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough,...

Via Newsfile

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 07, 2025

Via Benzinga

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

May 07, 2025

Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior...

Via Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

May 01, 2025

Marlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing...

Via Newsfile

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.